Market Forecast
Meningococcal Vaccines Market share is projected to
be worth USD 6.80 billion by 2032, registering a CAGR of 7.3% during the
forecast period 2023 – 2032.
Market Synopsis
Meningococcal meningitis is a bacterial infection
caused by Neisseria meningitides. Disease incidence is high in West and Central
Africa, where historically, serogroup A has been the most important cause of
disease. More recently, meningitis outbreaks have gradually been associated
with serogroup C, and to a lesser extent, serogroup W.
The meningococcal vaccines market is complex and
diverse, with regional variations in serogroup distribution with substantial
use outside routine immunization. The vaccine has approximately 29 marketed
products targeting various combinations of the six serogroups (A, B, C, W, X, Y).
Competitive landscape
The meningococcal
vaccines market players are below.
- Baxter international
- Pfizer Inc.
- Sanofi S.A.
- Novartis Pharmaceuticals Inc.
- JN-International Medical Corporation
- Serum Institute of India Ltd.
- GlaxoSmithKline
- BIO-MED
- OthersTop of Form
Market Influencer
Without an
increase in production, the existing supply of conjugate MenACWY will be
inadequate to meet the demand generated by the rising incidence of serogroups C
and W, and the low availability of polysaccharide vaccines. Further, several
multivalent, conjugate vaccines by Chinese and Indian manufacturers are in the
pipeline, and, if prequalified they will be registered for use in many
geographies. Moreover, if they are made available at acceptable prices it could
increase global demand in Meningococcal
Vaccines Market Trends.
Meningococcal
Vaccines Market Segmentation
By treatment, the market is segmented into
Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine.
Meningococcal A conjugate vaccine is significantly used in mass
campaigns across affected regions like Africa. Since 2010, the vaccine has
significantly decreased meningococcal disease incidence in the region. However,
the demand for meningococcal A conjugate in the country remains uncertain given
that national immunization program adoptions are based on the timing of Gavi
funding decisions, the country’s readiness, and competing for vaccine
introduction priorities.
In the polysaccharide segment, products such as MenACWY vaccines are in
high demand. MenACWY vaccine is the most desirable combination, given its
broader serotype coverage. MenACWY specifically has nine products that are
available across polysaccharide and conjugate product segments, but conjugate
products are suggested for use in routine immunization activities.
Moreover, the demand and supply of Subcap MenB vaccines is restricted to
HICs and influenced by their acceptance into NIPs. Improved uptake of MenB
vaccines is expected in the coming years but will likely be moderate and
limited to high-income markets given the high price and competing interest of
introducing MenACWY conjugate.
By end-user, the market is segmented into Hospital
& Clinical, Research Laboratories, and Academic Institutes
Hospitals and clinics control the global meningococcal vaccines market research. The high growth of hospitals and clinics segment is attributed to the
increasing application of vaccines in these healthcare facilities in
conjunction with the growing prevalence and incidence of the meningococcal
disease.
Moreover, research laboratories and academic institutes take up the second-largest
share due to the boost in research and development in the market.
By region, the market is segmented into the
Americas, Europe, Asia-Pacific, and the Middle East & Africa.
In the global market, China is expected to have the
largest market share, which accounts for approximately 35% of the global
demand. This is primarily due to polysaccharide products, which currently
comprise 84% of China’s demand. Chinese suppliers presently focus only on
meeting the demand of the domestic market, but some of the manufacturers have
indicated interest in the global market as well. The dynamic product pipeline
with several multivalent conjugate products in development may trigger changes in
the future supply mix of the Chinese market. Moreover, in China, non-routine
use (excluding campaigns) accounts for an estimated 9 million doses in 2019,
which may help to sustain the huge market share in the forecast period.
UNICEF foresees all 26 African countries in the meningitis belt, which
have completed mass campaigns in 2016. In 2015, seven countries in the region
were introduced with meningococcal A conjugate vaccine through their mass
campaigns and targeted a population of 233 million. Further, during 2016-2018,
UNICEF introduced meningococcal A conjugate vaccine in 26 countries. Ghana was
the first country to be introduced with the vaccine into its RI schedule in
2016. Also, four other countries including Mali, Niger, Nigeria, and Sudan
introduced the vaccine into RI programs in 2016.
Market
Research Future (MRFR), enable customers to unravel the complexity of various
industries through Cooked Research Report (CRR), Half-Cooked Research Reports
(HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market
Research & Consulting Services.
Contact us:
Market
Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson
Street,5Th Floor, New York,
New York 10013
United States
of America
